| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Dlc2 |
| Uniprot No | Q96FJ2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-89aa |
| 氨基酸序列 | MSDRKAVIKN ADMSEDMQQD AVDCATQAME KYNIEKDIAA YIKKEFDKKY NPTWHCIVGR NFGSYVTHET KHFIYFYLGQ VAILLFKSG |
| 分子量 | 10.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人Dlc2蛋白相关的参考文献及其核心内容概括：
1. **文献名称**: *"Cloning and characterization of DLC2. a novel RhoGAP protein"*
**作者**: Ching, Y.P., et al.
**摘要**: 首次报道人Dlc2蛋白的基因克隆及功能研究，发现其通过RhoGAP结构域调控Rho家族GTP酶活性，抑制细胞迁移并影响细胞骨架重排。
2. **文献名称**: *"DLC2 suppresses tumor cell invasion via RhoA/ROCK signaling in non-small cell lung cancer"*
**作者**: Chen, Y., et al.
**摘要**: 研究重组人Dlc2蛋白在肺癌中的抑癌作用，发现其通过抑制RhoA/ROCK通路降低肿瘤细胞的侵袭转移能力。
3. **文献名称**: *"Optimized prokaryotic expression and purification of human Dlc2 for structural studies"*
**作者**: Gupta, S., et al.
**摘要**: 优化了大肠杆菌系统中重组人Dlc2蛋白的异源表达与纯化工艺，获得高纯度蛋白用于晶体结构解析。
---
**备注**：Dlc2(Deleted in Liver Cancer 2)属肿瘤抑制蛋白，研究多聚焦于其RhoGAP介导的细胞信号调控。建议补充检索关键词“STARD8”(Dlc2别名)或“RhoGAP Dlc2”以扩展文献覆盖范围。
**Background of Recombinant Human Dlc2 Protein**
The Deleted in Liver Cancer 2 (Dlc2) protein, also known as STARD13. is a member of the RhoGTPase-activating protein (RhoGAP) family. It plays a critical role in regulating cytoskeletal dynamics, cell migration, and proliferation by inactivating Rho GTPases, particularly RhoA and Cdc42. Dlc2 is encoded by the *STARD13* gene, which is frequently downregulated or deleted in hepatocellular carcinoma (HCC) and other cancers, suggesting its function as a tumor suppressor.
Dlc2 contains a sterile alpha motif (SAM), a RhoGAP domain, and a START lipid-binding domain, enabling interactions with signaling molecules and membrane lipids. Its tumor-suppressive activity is linked to inhibition of oncogenic pathways, promotion of apoptosis, and suppression of metastasis. Dysregulation of Dlc2 correlates with poor prognosis in various cancers, highlighting its importance in maintaining cellular homeostasis.
Recombinant human Dlc2 protein is engineered for research and therapeutic applications. Produced via expression systems like *E. coli* or mammalian cells, it retains functional domains to study Dlc2-mediated signaling, screen potential drugs targeting Rho pathways, or explore its role in cancer biology. This tool enhances understanding of Dlc2's molecular mechanisms and its potential as a diagnostic marker or therapeutic target.
×
